News & Updates

Adding the anti-PD-1 monoclonal antibody tislelizumab to chemotherapy in the first-line treatment of PD-1-positive advanced gastric or gastroesophageal junction adenocarcinoma appears to produce significant and clinically meaningful improvements in survival outcomes while having an acceptable safety profile, according to interim data from the phase III RATIONALE 305 trial.

Treatment with the dual PPAR α/γ agonist saroglitazar helps improve the serum atherogenic lipoprotein profile in patients with nonalcoholic fatty liver disease (NAFLD), regardless of comorbid conditions and statin use, as shown in a study.

Giving chemotherapy to patients with synchronous and unresectable liver metastases from colorectal cancer before undergoing primary tumour resection helps boost survival outcomes, according to a phase III trial presented at this year’s ASCO Gastrointestinal Cancer Symposium (ASCO GI).

The addition of somatostatin to rectal indomethacin is safe and effective in the prevention of postendoscopic retrograde cholangiopancreatography (post-ERCP) hypermylasemia and pancreatitis (PEP) in high-risk patients, reports a study.

A study from Israel validated the safety of the fourth BNT162b2 mRNA COVID-19 vaccine (ie, second booster) using data from a retrospective and a prospective cohort.

Insulin delivery via a bionic pancreas better controlled HbA_1c levels compared with standard of care (SoC) in patients with type 1 diabetes (T1D), according to a recent multicentre trial from the US.